Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback